As of 2025-09-13, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -4.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 452.65 mil USD. LXRX's TTM EBITDA according to its financial statements is -107.44 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 15.5x | 14.2x |
| Forward P/E multiples | 17.7x - 27.0x | 21.0x |
| Fair Price | (5.33) - (4.67) | (5.30) |
| Upside | -563.9% - -505.8% | -560.8% |
| Date | EV/EBITDA |
| 2025-09-09 | -4.15 |
| 2025-09-08 | -3.98 |
| 2025-09-05 | -4.01 |
| 2025-09-04 | -3.94 |
| 2025-09-03 | -3.98 |
| 2025-09-02 | -4.11 |
| 2025-08-29 | -4.04 |
| 2025-08-28 | -4.21 |
| 2025-08-27 | -4.15 |
| 2025-08-26 | -4.18 |
| 2025-08-25 | -4.15 |
| 2025-08-22 | -4.35 |
| 2025-08-21 | -4.28 |
| 2025-08-20 | -4.15 |
| 2025-08-19 | -4.25 |
| 2025-08-18 | -4.42 |
| 2025-08-15 | -4.52 |
| 2025-08-14 | -4.31 |
| 2025-08-13 | -4.08 |
| 2025-08-12 | -3.91 |
| 2025-08-11 | -3.84 |
| 2025-08-08 | -3.98 |
| 2025-08-07 | -4.11 |
| 2025-08-06 | -4.21 |
| 2025-08-05 | -3.87 |
| 2025-08-04 | -4.11 |
| 2025-08-01 | -3.94 |
| 2025-07-31 | -3.94 |
| 2025-07-30 | -3.77 |
| 2025-07-29 | -3.94 |
| 2025-07-28 | -4.01 |
| 2025-07-25 | -4.04 |
| 2025-07-24 | -4.15 |
| 2025-07-23 | -4.42 |
| 2025-07-22 | -4.38 |
| 2025-07-21 | -4.48 |
| 2025-07-18 | -4.48 |
| 2025-07-17 | -4.89 |
| 2025-07-16 | -4.69 |
| 2025-07-15 | -4.21 |
| 2025-07-14 | -4.31 |
| 2025-07-11 | -3.98 |
| 2025-07-10 | -4.15 |
| 2025-07-09 | -3.94 |
| 2025-07-08 | -3.42 |
| 2025-07-07 | -3.28 |
| 2025-07-03 | -3.37 |
| 2025-07-02 | -3.42 |
| 2025-07-01 | -3.31 |
| 2025-06-30 | -3.52 |